SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "AMNE:(MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi) "

Sökning: AMNE:(MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Bin Kaderi, Mohamed Arifin, 1978- (författare)
  • Assessment of Novel Molecular Prognostic Markers in Chronic Lymphocytic Leukemia
  • 2010
  • Doktorsavhandling (övrigt vetenskapligt)abstract
    • <p>The clinical course of chronic lymphocytic leukemia (CLL) is highly heterogeneous, which has prompted<sup> </sup>the search for biomarkers that can predict prognosis in this disease. The IGHV gene mutation status and certain genomic aberrations have been identified as reliable prognostic markers of clinical outcome for this disorder. However, the search for more feasible prognostic markers in CLL is still being pursued. Recently, certain single nucleotide polymorphisms (SNPs) in the <em>GNAS1</em>, <em>BCL2</em> and <em>MDM2</em> genes and the RNA expression levels of the <em>LPL</em>, <em>ZAP70</em>, <em>TCL1, CLLU1 </em>and <em>MCL1</em> genes were suggested as novel prognostic markers in CLL.</p> <p>In papers I-III, we performed genotyping analyses of the <em>GNAS1</em> T393C, <em>BCL2</em> -938C&gt;A and <em>MDM2</em> SNP309 polymorphisms in 268-418 CLL patients and related the genotypes with clinical data. Association studies between the polymorphisms and established prognostic markers (i.e. IGHV mutation status, genomic aberrations, CD38 expression) were also performed. Our studies did not find any significant relationship between these SNPs with either clinical outcome or other known prognostic markers in CLL.</p> <p>In paper IV, we measured the RNA expression levels of <em>LPL</em>, <em>ZAP70</em>, <em>TCL1,</em> <em>CLLU1</em> and <em>MCL1</em> in 252 CLL cases and correlated these levels with clinical outcome. Here, we verified that high expression of all these RNA-based markers, except <em>MCL1</em>, were associated with an unfavourable prognosis. We also confirmed a close relationship between IGHV mutation status and the RNA-based markers, especially for <em>LPL</em> and <em>CLLU1</em> expression. Among the RNA-based markers, multivariate analysis revealed <em>LPL</em> expression as the strongest independent prognostic marker for overall survival and time to treatment. Furthermore, the RNA-based markers could add further prognostic information to established markers in subgroups of patients, with <em>LPL</em> expression status giving the most significant results.</p> <p>In summary, data from papers I-III could not verify the <em>GNAS1</em> T393C, <em>BCL2</em> -938C&gt;A and <em>MDM2 </em>SNP309 polymorphisms as prognostic markers in CLL. Future SNP markers must hence be confirmed in large, independent cohorts before being proposed as prognostic marker in CLL. In paper IV, we conclude that <em>LPL</em> expression appears to be the strongest among the RNA-based markers for CLL prognostication. Further efforts to standardize <em>LPL</em> quantification are required before it can be applied in the clinical laboratory to predict clinical outcome in this disease.<em></em></p>
2.
  •  
3.
  • Browall, Maria, et al. (författare)
  • Information needs of women with recently diagnosed ovarian cancer - A longitudinal study
  • 2004
  • Ingår i: European Journal of Oncology Nursing. - Elsevier. - 1462-3889 .- 1532-2122. ; 8:3, s. 200-207
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>The aim of this study was to investigate the information needs among patients with ovarian cancer and whether these information needs change over time. The information needs were evaluated three times, through structured interviews, and were based on the paired comparison approach developed by Degner and colleagues. A consecutive sample of patients (n=82) with recently diagnosed ovarian cancer was asked to participate.Sixty-four patients (78%) chose to participate. The three different measurements of participants' information needs revealed only small changes in these needs. The three most important information needs, in all measurements, were information about the likelihood of cure, information about the stage and spreading of the disease, and information about different treatment options. Information regarding sexual attractiveness was the lowest ranked item in all measurements. Regarding subgroups (age, education) the only significant difference throughout all measurements was that younger patients rated issues of sexual attractiveness higher than older patients (p=0.005).In this longitudinal study patients with ovarian cancer ranked information about the disease and its treatment (i.e. likelihood of cure, stage of disease, and treatment options) highest, and information about psychosocial aspects and self-care lowest. These findings are in accordance with the results from studies of women diagnosed with other types of cancer, which used the same methodology. © 2004 Elsevier Ltd. All rights reserved.</p>
  •  
4.
  • Lönnbro-Widgren, Jennie, et al. (författare)
  • Glomerular IgG subclasses in idiopathic and malignancy-associated membranous nephropathy
  • 2015
  • Ingår i: Clinical Kidney Journal. - 1753-0784 .- 1753-0792. ; 8:4, s. 433-439
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: In idiopathic membranous nephropathy (MN), antibodies directed towards the glomerular phospholipase A<inf>2</inf> receptor (PLA<inf>2</inf>R) have mainly been reported to be of IgG4 subclass. However, the role of the different IgG subclasses in the pathogenesis of MN, both in idiopathic MN and in secondary cases, is still unclear. In this retrospective study, we test the hypothesis that the absence of glomerular IgG4 and PLA<inf>2</inf>R in patients with MN indicates malignant disease. Methods: The distribution pattern of glomerular IgG subclasses and PLA<inf>2</inf>Rwas studied in 69 patients with idiopathicMNand 16 patients with malignancy-associated MN who were followed up for a mean of 83 months. Results: A significant correlation between the absence of IgG4 and PLA<inf>2</inf>R and malignancy-associatedMNwas found. Thus, IgG4 was positive in 45 of 69 patients (65%) with idiopathicMNbut only in 5 of 16 patients (31%) with malignancy-associated MN. The other IgG subclasses did not differ statistically between the groups, IgG2-positivity being present in more than 94% of patients in both groups. Thirty-five of 63 patients (56%) with idiopathic MN and 3 of 16 (19%) patients with malignancy-associated MN had glomerular deposits of PLA<inf>2</inf>R. Conclusions: We have found that the absence of glomerular IgG4 and PLA<inf>2</inf>R iscommonin patients with malignancy-associated MN. In our material, IgG2 could not be used as a marker of underlying malignant disease. Finally, neither IgG1 nor IgG3 seems to be involved in the pathogenesis of MN. © The Author 2015.
  •  
5.
  • Ge, Chenjie, et al. (författare)
  • Enlarged Training Dataset by Pairwise GANs for Molecular-Based Brain Tumor Classification
  • 2020
  • Ingår i: IEEE Access. - 2169-3536. ; 8:1, s. 22560-22570
  • Tidskriftsartikel (refereegranskat)abstract
    • This paper addresses issues of brain tumor subtype classification using Magnetic Resonance Images (MRIs) from different scanner modalities like T1 weighted, T1 weighted with contrast-enhanced, T2 weighted and FLAIR images. Currently most available glioma datasets are relatively moderate in size, and often accompanied with incomplete MRIs in different modalities. To tackle the commonly encountered problems of insufficiently large brain tumor datasets and incomplete modality of image for deep learning, we propose to add augmented brain MR images to enlarge the training dataset by employing a pairwise Generative Adversarial Network (GAN) model. The pairwise GAN is able to generate synthetic MRIs across different modalities. To achieve the patient-level diagnostic result, we propose a post-processing strategy to combine the slice-level glioma subtype classification results by majority voting. A two-stage course-to-fine training strategy is proposed to learn the glioma feature using GAN-augmented MRIs followed by real MRIs. To evaluate the effectiveness of the proposed scheme, experiments have been conducted on a brain tumor dataset for classifying glioma molecular subtypes: isocitrate dehydrogenase 1 (IDH1) mutation and IDH1 wild-type. Our results on the dataset have shown good performance (with test accuracy 88.82%). Comparisons with several state-of-the-art methods are also included.
6.
  • Sorbe, Bengt, et al. (författare)
  • Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up
  • 2008
  • Ingår i: International Journal of Gynecological Cancer. - Blackwell Publishing Ltd. - 1048-891X .- 1525-1438. ; 18:4, s. 803-808
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>There is no generally accepted standard chemotherapy in treatment of advanced and recurrent endometrial carcinoma. Cisplatin and doxorubicin with or without cyclophosphamide are widely used. Response rates have improved with combination chemotherapy compared with single-agent therapy. A platinum analog seems to be an important part of the chemotherapy regimen. Since few patients are cured from their disease and since the duration of response is short, further improvement of this therapy is warranted. During the past years, the taxanes (paclitaxel) are being added to prior evaluated regimens and not only improved response rates are reported but also increased toxicity is observed. In a prospective, phase II, multicenter study, carboplatin (area under the curve = 5) and paclitaxel (175 mg/m(2)) were evaluated in treatment of primary advanced and recurrent endometrial carcinoma. In total, 66 patients were recruited during the years 2000-2004. Eighteen primary advanced tumors and 48 recurrences were treated. All histologic types and tumor grades were allowed. The median follow-up was 57 months (range 37-69 months). The overall response rate was 67% (95% CI 55-78). The complete response rate was 29% and the partial response rate 38%. Primary advanced and recurrent tumors as well as endometrioid and nonendometrioid tumors showed similar response rates. The median response duration was 14 months. The 1- and 3-year survival rates were 82% and 33%, respectively. The main toxicities were hematologic and neurologic (sensory neuropathy). The response rates were encouraging, superior to prior platinum-containing regimens, but response duration and the long-term survival rate were still short. The neurologic toxicity was frequent and was a substantial problem in this series of patients. Further research is highly needed to improve the treatment of advanced and recurrent endometrial cancer.</p>
  •  
7.
  • Tomlins, Scott A., et al. (författare)
  • The role of SPINK1 in ETS rearrangement-negative prostate cancers
  • 2008
  • Ingår i: Cancer Cell. - Amsterdam : Elsevier. - 1535-6108 .- 1878-3686. ; 13:6, s. 519-28
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>ETS gene fusions have been characterized in a majority of prostate cancers; however, the key molecular alterations in ETS-negative cancers are unclear. Here we used an outlier meta-analysis (meta-COPA) to identify SPINK1 outlier expression exclusively in a subset of ETS rearrangement-negative cancers ( approximately 10% of total cases). We validated the mutual exclusivity of SPINK1 expression and ETS fusion status, demonstrated that SPINK1 outlier expression can be detected noninvasively in urine, and observed that SPINK1 outlier expression is an independent predictor of biochemical recurrence after resection. We identified the aggressive 22RV1 cell line as a SPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement-negative prostate cancers.</p>
  •  
8.
  • Möllerberg, Marie-Louise, et al. (författare)
  • The effects of a cancer diagnosis on the health of a patient's partner : a population-based registry study of cancer in Sweden
  • 2016
  • Ingår i: European Journal of Cancer Care. - 0961-5423 .- 1365-2354. ; 25:5, s. 744-752
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>The aim of this population-based registry study was to explore how cancer influences the health of partners, by examining the onset of new diagnoses for partners, health care use and health care costs among partners living with patients with cancer. The sample consisted of partners of patients with cancer (N = 10 353) and partners of age- and sex-matched controls who did not have cancer (N = 74 592). Diagnoses, health care use and health care costs were studied for a continuous period starting 1 year before the date of cancer diagnosis and continued for 3 years. One year after cancer diagnosis, partners of patients with cancer had significantly more mood disorders, reactions to severe stress and ischaemic heart disease than they exhibited in the year before the diagnosis. Among partners of patients with cancer, the type of cancer was associated with the extent and form of increased health care use and costs; both health care use and costs increased among partners of patients with liver cancer, lung cancer, colon cancer and miscellaneous other cancers. The risk of poorer health varied according to the type of cancer diagnosed, and appeared related to the severity and prognosis of that diagnosis.</p>
  •  
9.
  • Bergengren, O., et al. (författare)
  • Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study
  • 2018
  • Ingår i: European Urology Oncology. - 2588-9311. ; 1:1, s. 37-45
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Information about how men with prostate cancer (PC) experience their medical care and factors associated with their overall satisfaction with care (OSC) is limited. Objective: To investigate OSC and factors associated with OSC among men with low-risk PC. Design, setting, and participants: Men registered in the National Prostate Cancer Register of Sweden as diagnosed in 2008 with low-risk PC at the age of ≤70 yr who had undergone radical prostatectomy (RP), radiotherapy (RT), or started on active surveillance (AS) were invited in 2015 to participate in this nationwide population-based survey (n = 1720). Outcome measurements and statistical analysis: OSC data were analysed using ordinal logistic regression. Odds ratios (ORs) were calculated for comparisons between the highest and lowest possible response categories. Results and limitations: A total of 1288 men (74.9%) responded. High OSC was reported by 958 (74.4%). Factors associated with high OSC were high participation in decision-making (OR 4.18, 95% confidence interval [CI] 2.61–6.69), receiving more information (OR 11.1, 95% CI 7.97–15.6), high-quality information (OR 7.85, 95% CI 5.46–11.3), access to a nurse navigator (OR 1.80, 95% CI 1.44–2.26), and better functional outcomes (defined as 25 points higher on the EPIC-26 questionnaire; OR 1.34, 95% CI 1.21–1.48). OSC was not affected by whether a doctor or specialist nurse conducted follow-up (OR 0.84, 95% CI 0.66–1.07). These findings were similar across treatment groups. Men who had undergone RP or RT reported high OSC more often than men on AS (78.2% vs 84.0% vs 72.6%), high participation in decision-making (70.5% vs 64.5% vs 49.2%), and having received more information (40.5% vs 45.8% vs 28.6%), and were less likely to believe they would die from PC (3.8% vs 3.9% vs 8.0%). Limitations include the nonrandomised retrospective design and potential recall bias. Conclusions: Information and participation in decision-making, as well as access to a nurse navigator, are key factors for OSC, regardless of treatment. Men on AS need more information about their treatment and need to participate more in decision-making. OSC was as high among men who had nurse-led follow-up as among men who had doctor-led follow-up. Patient summary: Information about how men with low-risk prostate cancer experience their medical care is limited. In this nationwide population-based study we found that information and participation in decision-making as well as access to a nurse navigator are key factors for satisfaction regardless of treatment. Men who are being closely watched for prostate cancer without immediate curative treatment need more information than they now receive and need to participate more in decision-making than they currently do. Information and participation in decision-making are key factors for satisfaction with care among men with localised prostate cancer. Men under active surveillance need more information about their treatment and need to participate more in decision-making. © 2018 European Association of Urology
  •  
10.
  • Tzortzatos, Gerasimos, et al. (författare)
  • The gynecological surveillance of women with Lynch Syndrome in Sweden
  • 2015
  • Ingår i: Gynecologic Oncology. - 0090-8258. ; 138:3, s. 717-722
  • Tidskriftsartikel (refereegranskat)abstract
    • Women with Lynch syndrome (LS) have up to a 60% lifetime risk of endometrial cancer (EC) and up to a 24% risk of ovarian cancer (OC). Gynecological surveillance is recommended, but the benefit and how it should be performed remain unclear. The purpose of this study was to assess diagnostic modalities for gynecological screening of LS patients in Sweden and clinical outcome.
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (3267)
Typ av publikation
tidskriftsartikel (11241)
doktorsavhandling (568)
forskningsöversikt (484)
konferensbidrag (470)
annan publikation (151)
bokkapitel (115)
visa fler...
rapport (18)
bok (12)
samlingsverk (redaktörskap) (7)
licentiatavhandling (4)
recension (3)
proceedings (redaktörskap) (1)
patent (1)
visa färre...
Typ av innehåll
refereegranskat (11462)
övrigt vetenskapligt (2218)
populärvet., debatt m.m. (27)
Författare/redaktör
Trichopoulou, Antoni ... (433)
Riboli, Elio (426)
Tumino, Rosario (400)
Overvad, Kim (393)
Boeing, Heiner (375)
Khaw, Kay-Tee (354)
visa fler...
Olsson, Håkan, (350)
Kaaks, Rudolf (347)
Palli, Domenico (299)
Weiderpass, Elisabet ... (296)
Jirström, Karin, (282)
Boutron-Ruault, Mari ... (280)
Borg, Åke, (270)
Manjer, Jonas, (268)
Tjonneland, Anne (260)
Hemminki, Kari, (252)
Panico, Salvatore (244)
Bueno-de-Mesquita, H ... (239)
Stattin, Pär, (230)
Vineis, Paolo (230)
Sanchez, Maria-Jose (228)
Glimelius, Bengt, (203)
Travis, Ruth C (202)
Trichopoulos, Dimitr ... (200)
Trichopoulou, A (198)
Riboli, E (197)
Fernö, Mårten, (189)
Tumino, R (187)
Overvad, K (186)
Barricarte, Aurelio (186)
Tjønneland, Anne (186)
Ardanaz, Eva (186)
Tjonneland, A (184)
Clavel-Chapelon, Fra ... (178)
Steineck, G, (178)
Dasu, Alexandru (176)
Boeing, H (172)
Peeters, Petra H. (170)
Kaaks, R (170)
Jenab, Mazda (167)
Forssell-Aronsson, E ... (167)
Lagiou, Pagona (165)
Henriksson, Roger, (163)
Toma-Dasu, Iuliana, (162)
Bendahl, Pär Ola, (161)
Dorronsoro, Miren (161)
Sacerdote, Carlotta (159)
Peeters, Petra H M (159)
Weiderpass, E, (157)
Steineck, Gunnar, 19 ... (157)
visa färre...
Lärosäte
Lunds universitet (5747)
Göteborgs universitet (2223)
Uppsala universitet (1864)
Umeå universitet (1763)
Karolinska Institutet (1657)
Örebro universitet (520)
visa fler...
Linköpings universitet (475)
Stockholms universitet (207)
Chalmers tekniska högskola (166)
Kungliga Tekniska Högskolan (88)
Jönköping University (64)
Högskolan i Skövde (36)
Sveriges Lantbruksuniversitet (33)
Linnéuniversitetet (31)
Sophiahemmet Högskola (12)
Gymnastik- och idrottshögskolan (10)
Ersta Sköndal Bräcke högskola (10)
Röda Korsets Högskola (10)
Mittuniversitetet (9)
Högskolan i Borås (9)
Högskolan Väst (8)
swepub_uni:mau_t (7)
Högskolan Kristianstad (6)
Södertörns högskola (6)
Högskolan i Gävle (6)
Karlstads universitet (4)
Högskolan i Halmstad (3)
Blekinge Tekniska Högskola (3)
Mälardalens högskola (1)
RISE (1)
Försvarshögskolan (1)
Högskolan Dalarna (1)
visa färre...
Språk
Engelska (12646)
Svenska (149)
Danska (3)
Spanska (3)
Isländska (3)
Annat språk (3)
visa fler...
Norska (2)
Tyska (1)
Odefinierat språk (1)
Polska (1)
Kinesiska (1)
Ukrainska (1)
visa färre...
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (13075)
Naturvetenskap (320)
Samhällsvetenskap (102)
Teknik (64)
Lantbruksvetenskap (19)
Humaniora (16)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy